001060 — JW Pharmaceutical Balance Sheet
0.000.00%
- KR₩766bn
- KR₩885bn
- KR₩749bn
- 95
- 54
- 72
- 90
Annual balance sheet for JW Pharmaceutical, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 41,864 | 55,291 | 37,366 | 40,072 | 15,909 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 184,221 | 128,146 | 187,620 | 218,562 | 203,629 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 335,057 | 299,329 | 366,452 | 425,457 | 378,091 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 150,430 | 185,572 | 118,392 | 123,048 | 155,724 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 573,208 | 549,085 | 633,053 | 627,973 | 645,039 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 277,983 | 234,748 | 282,678 | 380,131 | 286,927 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 343,126 | 341,594 | 431,858 | 387,619 | 379,598 |
Redeemable Preferred Stock | |||||
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 230,082 | 207,491 | 201,195 | 240,354 | 265,440 |
Total Liabilities & Shareholders' Equity | 573,208 | 549,085 | 633,053 | 627,973 | 645,039 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |